

Lung Cancer Quality Performance Indicator Specifications

LCQI07 Systemic Anti-cancer Therapy

2021

Citation: Te Aho o Te Kahu. 2021. *Lung Cancer Quality Performance Indicator Specifications: LCQI07 Systemic Anti-cancer Therapy*. Wellington: Te Aho o Te Kahu.

Published in March 2021 by the Te Aho o Te Kahu
PO Box 5013, Wellington 6140, New Zealand

ISBN 978-1-99-002988-2 (online)
HP 7603



This document is available at teaho.govt.nz



This work is licensed under the Creative Commons Attribution 4.0 International licence. In essence, you are free to: share ie, copy and redistribute the material in any medium or format; adapt ie, remix, transform and build upon the material. You must give appropriate credit, provide a link to the licence and indicate if changes were made.

Contents

Introduction	1
Sources of data for indicator	1
LCQI07 Systemic anti-cancer therapy	2
Measure items	2
Case eligibility criteria (denominator)	3
Numerator criteria	5
Chemotherapy drug codes and names	6

Introduction

This information is provided to make it easier for analysts to replicate our calculations. For each measure we have provided supporting information, a table and a flow diagram.

This document provides specifications for the following measure.

Measure	Measure abbreviation	Measure type
a) Proportion of people with non-small cell lung cancer receiving systemic anti-cancer therapy	NSCLC_SACT	Quality improvement
b) Proportion of people with small cell lung cancer receiving systemic anti-cancer therapy	SCLC_SACT	Quality improvement

Sources of data for indicator

- New Zealand Cancer Registry (NZCR) – a population-based register of all primary malignant diseases diagnosed in New Zealand, excluding squamous and basal cell skin cancers
- Pharmaceutical Collection (PHARMS) – a data warehouse that supports the management of pharmaceutical subsidies, and contains claim and payment information from pharmacists for subsidised dispensings

More information on these data sources can be found on the Ministry of Health's website: www.health.govt.nz.

LCQI07

Systemic anti-cancer therapy

- a) Proportion of people with non-small cell lung cancer receiving systemic anti-cancer therapy.
- b) Proportion of people with small cell lung cancer receiving systemic anti-cancer therapy.

Measure type: quality improvement

Measure items

Dataset	Data item	Description
NZCR	NHI	Patient identifier
NZCR	Cancer event ID	Cancer registration identifier
NZCR	Date of initial diagnosis	Date person first diagnosed with lung cancer
NZCR	Diagnosis year	Calendar year of first diagnosis
NZCR	Site	Primary organ of origin of the cancer (ICD-10-AM 8 th Edition code)
NZCR	Morphology code	4-digit code (ICD-O-3) for microscopic or cellular anatomy of the cancer
NZCR	Basis	Basis of diagnosis
NZCR	DHB of domicile	DHB code for domicile of patient at diagnosis
NZCR	DHB	DHB name based on domicile of patient at diagnosis
NZCR	Age at diagnosis	Age of patient at diagnosis in years
NZCR	Prioritised ethnicity	Ethnic group derived from patient's ethnicity
NZCR	Sex	Sex of patient
NZCR	Deprivation quintile	NZDep2013 index of social deprivation quintile based on patient's domicile
NZCR	Date of death	Date patient died
NZCR	TNM_T	Stage at diagnosis – tumour
NZCR	TNM_N	Stage at diagnosis – node
NZCR	TNM_M	Stage at diagnosis – metastases

Dataset	Data item	Description
NZCR	Behaviour code	Neoplastic behaviour of the cancer
NZCR	Multiple tumour flags	Person diagnosed with more than one tumour
NZCR	Registration status code	Status of registration processing
PHARMS	Date of dispensing	Date of dispensing of chemotherapy drugs
PHARMS	Funding DHB code	Code of DHB of service
PHARMS	Funding DHB	DHB of service for patient
PHARMS	Chemical ID	Identifier for drug
PHARMS	Chemical name	Name of chemotherapy drug

Case eligibility criteria (denominator)

a) NSCLC

Diagram reference	Assessment	Item	Codes
1	First or only diagnosis of malignant neoplasm	Primary site	First diagnosis of lung cancer (trachea C33 or bronchus C34)
2	Exclude manually censored case	Exclusion	Registration codes not R_C (registered complete) or R_R (registered) No incident cancer (exclude people with multiple tumour flags = yes) People diagnosed following death certificate only (basis = 0) People domiciled outside of New Zealand (DHB_code = 999) Cancer morphologies of melanoma, sarcoma and other unusual morphologies (codes 8333, 8720, 8772, 8800, 8801, 8803, 8805, 8815, 8890, 9040, 9041, 9133)
3	Diagnosis date	Date of initial diagnosis	2015–18
4	Male or female	Sex	M or F
5	Adult patient 18 years and older at diagnosis	Age at diagnosis	18 years and older
6	Invasive tumours	Behaviour code	3

7	Non-small cell lung cancer	Morphology code	Include all morphology codes except codes for SCLC (8041, 8042, 8043, 8044 and 8054) and other/unspecified lung cancers (8000, 8010, 8020, 8240, 8244, 8249)
---	----------------------------	-----------------	--

b) SCLC

Diagram reference	Assessment	Item	Codes
1	First or only diagnosis of malignant neoplasm	Primary site	First diagnosis of lung cancer (trachea C33 or bronchus C34)
2	Exclude manually censored case	Exclusion	Registration codes not R_C (registered complete) or R_R (registered) No incident cancer (exclude people with multiple tumour flags = yes) People diagnosed following death certificate only (basis = 0) People domiciled outside of New Zealand (DHB_code = 999) Cancer morphologies of melanoma, sarcoma and other unusual morphologies (codes 8333, 8720, 8772, 8800, 8801, 8803, 8805, 8815, 8890, 9040, 9041, 9133)
3	Diagnosis date	Date of initial diagnosis	2015–18
4	Male or female	Sex	M or F
5	Adult patient 18 years and older at diagnosis	Age at diagnosis	18 years and older
6	Invasive tumours	Behaviour code	3
7	Small cell lung cancer	Morphology code	Include SCLC morphology codes (80413, 80423, 80433, 80443 and 80543)

Numerator criteria

a) NSCLC

Diagram reference	Assessment	Item	Codes
8	Number of people with non-small cell lung cancer who receive systemic anti-cancer therapy	NSCLC_SACT	Drugs with chemical ID 3826, 3825, 2433, 3847, 3811, 3815, 3834, 3842, 3816, 4088, 3966, 3916, 1369, 3813, 2319, 2320


b) SCLC

Diagram reference	Assessment	Item	Codes
8	Number of people with small cell lung cancer who receive platinum-etoposide based systemic anti-cancer therapy	SCLC_SACT	Drugs with chemical ID 3826, 3825, 2433, 3847, 3811, 3815, 3834, 3842, 3816, 4088, 3966, 3916, 1369, 3813, 2319, 2320 and dispensed date between -30 and 275 days from diagnosis date

Chemotherapy drug codes and names

Chemical ID	Chemical name
3826	Cisplatin
3825	Carboplatin
2433	Etoposide
3847	Etoposide phosphate
3811	Irinotecan hydrochloride
3815	Paclitaxel
3834	Docetaxel
3842	Gemcitabine hydrochloride
3816	Vinorelbine
4088	Pemetrexed
3966	Gefitinib
3916	Erlotinib hydrochloride
1369	Cyclophosphamide
3813	Doxorubicin
2319	Vinblastine sulphate
2320	Vincristine sulphate

a) NSCLC



b) SCLC

